Why Pediatric ROTEM Needs Race-Specific Reference Ranges?
Vera Ignjatovic, Founder and Managing Director of Ignis Innovations Pty Ltd, shared a post by Journal of Thrombosis and Haemostasis (JTH) on LinkedIn:
”Here is the link to our paper describing the age and race-specific association of fibrinogen and Rotational Thromboelastometry (ROTEM) parameters in a diverse pediatric population.
Inclusion of a diverse population in establishing race-specific pediatric RIs has clinical and public health relevance for a more accurate diagnosis and personalized treatment.
Thank you, Marium Malik, Maha Al-Ghafry, Maribel Lema, Vijay Nandi, Linda Shore-Lesserson, and Suchitra S. Acharya for making this study possible. I am privileged to have worked with you in the late stages of this study.”
Quoting Journal of Thrombosis and Haemostasis (JTH)’s post:
”Association of fibrinogen and ROTEM parameters with age and race in a diverse pediatric population: a single-center study
By Marium Malik, Maha Al-Ghafry, Maribel Lema, Vijay Nandi, Vera Ignjatović, Linda Shore-Lesserson, and Suchitra S. Acharya
• Pediatric reference ranges for Rotational Thromboelastometry (ROTEM) – a whole-blood coagulation assay – are limited and rarely account for racial diversity.
• In 105 racially diverse children (1–21 years), investigators analyzed how age and race affect fibrinogen and ROTEM variables (EXTEM, INTEM, and FIBTEM).
• Fibrinogen and FIBTEM clot strength increased with age. Among Black/African American participants, rising age correlated with shorter clot times and stronger clot firmness, suggesting a prothrombotic hemostatic profile. This underscores the need for race-specific pediatric reference intervals for personalized coagulation assessment.
Read the article here.”
Title: Association of fibrinogen and Rotational Thromboelastometry (ROTEM) parameters with age and race in a diverse pediatric population: a single-center study
Authors: Marium Malik, Maha Al-Ghafry, Maribel Lema, Vijay Nandi, Vera Ignjatovic, Linda Shore-Lesserson, Suchitra S. Acharya

Stay updated with Hemostasis Today.
-
Mar 15, 2026, 15:55Rare Diseases, Plasma-Derived Medicines and the Elephant in the Room – Part 2
-
Mar 15, 2026, 14:09Abdul Mannan: A Red Eye, a Blood Clot, and Ibrutinib – The Clinical Tightrope
-
Mar 15, 2026, 14:02Denise M: Precision Hemostasis in Patient Blood Management
-
Mar 15, 2026, 13:57Abdulrahman Nasiri: D14 Bone Marrow Biopsy in AML Induction in the Era of Targeted Therapies
-
Mar 15, 2026, 13:52Valentin Ortiz-Maldonado: High-Impact Innovation in CAR-T Therapy Can Emerge From Academic Programmes
-
Mar 15, 2026, 13:45Tareq Abadl: Has Anyone Here Ever Taken an ALP Test Before?
-
Mar 14, 2026, 21:30Ayman Elbadawi: Why Does Stent Thrombosis Still Occur? Insights from the NCDR Data
-
Mar 14, 2026, 20:03Edward Adomako: Recognizing Thrombotic Thrombocytopenic Purpura as A Life-Threatening Emergency
-
Mar 14, 2026, 19:28Vishnu Priya Pulipati: Statins Beyond Cholesterol for Plaque Biology and Cardiovascular Risk Reduction